Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Emanuele Guardalben"'
Autor:
Marco Bellone, Lorenzo Pradelli, Rita Tavarozzi, Marco Ladetto, Giuliana Nepoti, Emanuele Guardalben, Daniela Ghislieri
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 23, Iss 1 (2022)
OBJECTIVE: To assess time- and cost-savings in relation to active time of health care professional (HCP) and resource consumption of administering obinutuzumab as a short duration infusion (SDI) in patients in treatment for Follicular Lymphoma (FL).
Externí odkaz:
https://doaj.org/article/13425f1eed7c4f0c8e1de77af0c6da82
Autor:
Cristina Tecchio, Angelo Andreini, Claudio Costantini, Alberto Zamò, Donata de Sabata, Fiorenza Aprili, Roberta Galavotti, Emanuele Guardalben, Fabio Benedetti
Publikováno v:
Hematology Reports, Vol 9, Iss 4 (2018)
The prognosis of patients affected by myelofibrosis (MF) is usually dismal and allogeneic hematopoietic stem cell transplantation (HSCT) remains the only cure. The number of HSCTs in MF patients has recently increased. However, a major obstacle is st
Externí odkaz:
https://doaj.org/article/ac444d9f52934852ab829116789a9ffc
Autor:
Massimiliano Bonifacio, Antonella Rigo, Emanuele Guardalben, Christian Bergamini, Elisabetta Cavalieri, Romana Fato, Giovanni Pizzolo, Hisanori Suzuki, Fabrizio Vinante
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e46674 (2012)
We showed that α-bisabolol is active against primary acute leukemia cells, including BCR-ABL(+) acute lymphoblastic leukemias (ALL). Here we studied the activity of α-bisabolol against BCR-ABL(+) cells using 3 cell lines (K562, LAMA-84, CML-T1) and
Externí odkaz:
https://doaj.org/article/d631495fc4384a45b5c0e11cdbd6b772
Autor:
Antonio Pinto, Emanuele Guardalben, Marco Caltagirone, Chiara Piparo, Caterina Patti, Elsa Pennese, Sonya De Lorenzo, Vincenzo Pavone, Ugo Consoli, Francesco Piazza, Monia Capponi, Benedetta Puccini, Luca Baldini, Alessandro Pulsoni, Stefan Hohaus, Piero Maria Stefani, Simone Santini, Vittorio Ruggero Zilioli, Caterina Stelitano, Luca Arcaini, Giuseppe Gritti, Marco Ladetto, Pier Luigi Zinzani
Publikováno v:
Blood. 140:3638-3641
Autor:
Antonio Pinto, Emanuele Guardalben, Marica Battista, Giulia Chiara Gazzoli, Michele Merli, Annalisa Chiarenza, Tommasina Perrone, Attilio Guarini, Nicola Di Renzo, Carlo Visco, Agostino Tafuri, Roberta Murru, Felicetto Ferrara, Jacopo Olivieri, Attilio Olivieri, Andrés J M Ferreri, Marco Ladetto, Pier Luigi Zinzani, Luca Arcaini, Giuseppe Gritti
Publikováno v:
Blood. 140:6504-6506
Autor:
Lorenzo Pradelli, Daniela Ghislieri, Antonietta Caputo, Emanuele Guardalben, Adele Emanuela De Francesco, Marco Bellone, Stefano Molica
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Marco Bellone,1 Lorenzo Pradelli,1 Stefano Molica,2 Adele Emanuela De Francesco,3 Daniela Ghislieri,4 Emanuele Guardalben,5 Antonietta Caputo4 1Department of Health Economics and Outcome Research, AdRes Health Economics and Outcomes Research, Turin,
Autor:
Elisa Tammiso, Massimo Negrini, Elena Saccenti, Eleonora Volta, Laura Lupini, Enrico Lista, Francesca Maria Quaglia, Antonio Urso, Francesco Cavazzini, Maurizio Cavallari, Cristian Bassi, Antonio Cuneo, Aurora Melandri, Luca Formigaro, Sara Martinelli, Maria Antonella Bardi, Gian Matteo Rigolin, Emanuele Guardalben
Publikováno v:
Oncotarget
Web of Science
Web of Science
We investigated whether karyotype analysis and mutational screening by next generation sequencing could predict outcome in 101 newly diagnosed chronic lymphocytic leukemia patients with high-risk features, as defined by the presence of unmutated IGHV
Autor:
Angelo Andreini, Emanuele Guardalben, Donata de Sabata, Fiorenza Aprili, Claudio Costantini, Alberto Zamò, Cristina Tecchio, Fabio Benedetti, Roberta Galavotti
Publikováno v:
Hematology Reports
Hematology Reports, Vol 9, Iss 4 (2018)
Hematology Reports, Vol 9, Iss 4 (2018)
The prognosis of patients affected by myelofibrosis (MF) is usually dismal and allogeneic hematopoietic stem cell transplantation (HSCT) remains the only cure. The number of HSCTs in MF patients has recently increased. However, a major obstacle is st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08166c9fb445ae2fae849bfe112e401e
http://hdl.handle.net/2318/1671208
http://hdl.handle.net/2318/1671208
Autor:
Laura Bonaldi, Antonio Cuneo, Gian Matteo Rigolin, Livio Trentin, Cristian Bassi, Luca Formigaro, Francesca Maria Quaglia, Francesca Romana Mauro, Caterina Ilari, Elisa Tammiso, Francesco Cavazzini, Gianpietro Semenzato, Luciana Cafforio, Robin Foà, Barbara Zagatti, Antonio Urso, Andrea Visentin, Aurora Melandri, Enrico Lista, Laura Lupini, Emanuele Guardalben, Eleonora Volta, Massimo Negrini, Elena Saccenti, Maurizio Cavallari, Maria Antonella Bardi
Publikováno v:
British journal of haematology. 181(2)
Complex karyotype (CK) is a negative prognostic factor in chronic lymphocytic leukaemia (CLL). However, CK is a heterogeneous cytogenetic category. Unbalanced rearrangements were present in 73·3% of 90 CLL patients with CK (i.e. ≥3 chromosome aber
Autor:
Massimo Negrini, Elisa Tammiso, Enrico Lista, Gian Matteo Rigolin, Emanuele Guardalben, Danilo Faraci, Cristian Bassi, Luca Formigaro, Eleonora Volta, Francesca Maria Quaglia, Carmine Liberatore, Antonio Urso, Elena Saccenti, Antonio Cuneo, Aurora Melandri, Maria Antonella Bardi, Laura Lupini, Maurizio Cavallari, Francesco Cavazzini
To the editor: Chronic lymphocytic leukemia (CLL) represents the most common form of leukemia in Western countries.[1][1] The clinical course of the disease is quite heterogeneous with some patients living for years with asymptomatic disease and othe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec67736ed220f3aa906d128f141d7c10
http://hdl.handle.net/11392/2373906
http://hdl.handle.net/11392/2373906